Circulating biomarkers of macrophage activation in different stages of chronic pancreatitis: A pilot study

Rasmus Hagn-Meincke; Srdan Novovic; Amer Hadi; Annette B. Jensen; Asbjørn M. Drewes; Henrik Kraup; Jens B. Frøkjær; Walter G. Park; Peter L. Jørgensen; Holger Jon Møller; Bent W. Deleuran; Søren S. Olesen

doi:10.1097/MPA.0000000000002443

Circulating biomarkers of macrophage activation in different stages of chronic pancreatitis: A pilot study

Rasmus Hagn-Meincke, Srdan Novovic, Amer Hadi, Annette B. Jensen, Asbjørn M. Drewes, Henrik Kraup, Jens B. Frøkjær, Walter G. Park, Peter L. Jørgensen, Holger Jon Møller, Bent W. Deleuran, Søren S. Olesen^*

^*Corresponding author for this work

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaper › Journal article › Research › peer-review

1 Citation (Scopus)

Abstract

Objectives: Activation of type M2 macrophages has been implicated in the pathogenesis of chronic pancreatitis (CP). In a clinical pilot study, we investigated blood-based markers of macrophage activation at different stages of CP. Materials and Methods: We performed a cross-sectional analysis of prospectively collected plasma samples from healthy controls and patients with suspected or definitive CP according to the M-ANNHEIM criteria. Plasma concentrations of soluble CD163 (sCD163), soluble CD206 (sCD206), and monocyte chemoattractant protein-1 (MCP-1) were analyzed using enzyme-linked immunosorbent assays. Group and pairwise comparisons of analytes were performed using regression models and area under the receiver operating curves (AUC-ROC). Results: In total, 73 subjects with CP (28 suspected CP and 45 definitive CP) and 40 controls were included. Compared to controls, the median plasma concentrations of sCD163 (P = 0.019) and sCD206 (P = 0.033) were elevated in patients with definitive CP. sCD206 was also elevated in patients with definitive CP (P = 0.042) compared to suspected CP. ROC analysis revealed the optimal sCD163 cutpoint to distinguish definitive CP from controls was 1.84 mg/mL (AUC-ROC 0.65; 95% confidence interval [CI], 0.54-0.77). The optimal sCD206 cutpoint to distinguish definitive CP from controls was 0.24 mg/mL (AUC-ROC 0.66; 95% CI, 0.54-0.78). MCP-1 concentrations showed no differences across subgroups. Conclusion: Our study demonstrates that subjects with definitive CP, sampled during a clinically quiescent phase, exhibited increased levels of sCD163 and sCD206. This indicates the presence of activated M2 macrophages in patients with CP at advanced, but not early, clinical stages.

Original language	English
Journal	Pancreas
Volume	54
Issue	4
Pages (from-to)	e331-e339
Number of pages	9
ISSN	0885-3177
DOIs	https://doi.org/10.1097/MPA.0000000000002443
Publication status	Published - Apr 2025

Keywords

biomarkers
chronic pancreatitis
immunology
macrophages

Access to Document

10.1097/MPA.0000000000002443

Cite this

@article{a2408e3ef3fa42579490ad7a15c5c329,

title = "Circulating biomarkers of macrophage activation in different stages of chronic pancreatitis: A pilot study",

abstract = "Objectives: Activation of type M2 macrophages has been implicated in the pathogenesis of chronic pancreatitis (CP). In a clinical pilot study, we investigated blood-based markers of macrophage activation at different stages of CP. Materials and Methods: We performed a cross-sectional analysis of prospectively collected plasma samples from healthy controls and patients with suspected or definitive CP according to the M-ANNHEIM criteria. Plasma concentrations of soluble CD163 (sCD163), soluble CD206 (sCD206), and monocyte chemoattractant protein-1 (MCP-1) were analyzed using enzyme-linked immunosorbent assays. Group and pairwise comparisons of analytes were performed using regression models and area under the receiver operating curves (AUC-ROC). Results: In total, 73 subjects with CP (28 suspected CP and 45 definitive CP) and 40 controls were included. Compared to controls, the median plasma concentrations of sCD163 (P = 0.019) and sCD206 (P = 0.033) were elevated in patients with definitive CP. sCD206 was also elevated in patients with definitive CP (P = 0.042) compared to suspected CP. ROC analysis revealed the optimal sCD163 cutpoint to distinguish definitive CP from controls was 1.84 mg/mL (AUC-ROC 0.65; 95% confidence interval [CI], 0.54-0.77). The optimal sCD206 cutpoint to distinguish definitive CP from controls was 0.24 mg/mL (AUC-ROC 0.66; 95% CI, 0.54-0.78). MCP-1 concentrations showed no differences across subgroups. Conclusion: Our study demonstrates that subjects with definitive CP, sampled during a clinically quiescent phase, exhibited increased levels of sCD163 and sCD206. This indicates the presence of activated M2 macrophages in patients with CP at advanced, but not early, clinical stages.",

keywords = "biomarkers, chronic pancreatitis, immunology, macrophages",

author = "Rasmus Hagn-Meincke and Srdan Novovic and Amer Hadi and Jensen, {Annette B.} and Drewes, {Asbj{\o}rn M.} and Henrik Kraup and Fr{\o}kj{\ae}r, {Jens B.} and Park, {Walter G.} and J{\o}rgensen, {Peter L.} and M{\o}ller, {Holger Jon} and Deleuran, {Bent W.} and Olesen, {S{\o}ren S.}",

note = "Publisher Copyright: Copyright {\textcopyright} 2024 Wolters Kluwer Health, Inc.",

year = "2025",

month = apr,

doi = "10.1097/MPA.0000000000002443",

language = "English",

volume = "54",

pages = "e331--e339",

journal = "Pancreas",

issn = "0885-3177",

publisher = "Lippincott Williams and Wilkins",

number = "4",

}

TY - JOUR

T1 - Circulating biomarkers of macrophage activation in different stages of chronic pancreatitis

T2 - A pilot study

AU - Hagn-Meincke, Rasmus

AU - Novovic, Srdan

AU - Hadi, Amer

AU - Jensen, Annette B.

AU - Drewes, Asbjørn M.

AU - Kraup, Henrik

AU - Frøkjær, Jens B.

AU - Park, Walter G.

AU - Jørgensen, Peter L.

AU - Møller, Holger Jon

AU - Deleuran, Bent W.

AU - Olesen, Søren S.

PY - 2025/4

Y1 - 2025/4

N2 - Objectives: Activation of type M2 macrophages has been implicated in the pathogenesis of chronic pancreatitis (CP). In a clinical pilot study, we investigated blood-based markers of macrophage activation at different stages of CP. Materials and Methods: We performed a cross-sectional analysis of prospectively collected plasma samples from healthy controls and patients with suspected or definitive CP according to the M-ANNHEIM criteria. Plasma concentrations of soluble CD163 (sCD163), soluble CD206 (sCD206), and monocyte chemoattractant protein-1 (MCP-1) were analyzed using enzyme-linked immunosorbent assays. Group and pairwise comparisons of analytes were performed using regression models and area under the receiver operating curves (AUC-ROC). Results: In total, 73 subjects with CP (28 suspected CP and 45 definitive CP) and 40 controls were included. Compared to controls, the median plasma concentrations of sCD163 (P = 0.019) and sCD206 (P = 0.033) were elevated in patients with definitive CP. sCD206 was also elevated in patients with definitive CP (P = 0.042) compared to suspected CP. ROC analysis revealed the optimal sCD163 cutpoint to distinguish definitive CP from controls was 1.84 mg/mL (AUC-ROC 0.65; 95% confidence interval [CI], 0.54-0.77). The optimal sCD206 cutpoint to distinguish definitive CP from controls was 0.24 mg/mL (AUC-ROC 0.66; 95% CI, 0.54-0.78). MCP-1 concentrations showed no differences across subgroups. Conclusion: Our study demonstrates that subjects with definitive CP, sampled during a clinically quiescent phase, exhibited increased levels of sCD163 and sCD206. This indicates the presence of activated M2 macrophages in patients with CP at advanced, but not early, clinical stages.

AB - Objectives: Activation of type M2 macrophages has been implicated in the pathogenesis of chronic pancreatitis (CP). In a clinical pilot study, we investigated blood-based markers of macrophage activation at different stages of CP. Materials and Methods: We performed a cross-sectional analysis of prospectively collected plasma samples from healthy controls and patients with suspected or definitive CP according to the M-ANNHEIM criteria. Plasma concentrations of soluble CD163 (sCD163), soluble CD206 (sCD206), and monocyte chemoattractant protein-1 (MCP-1) were analyzed using enzyme-linked immunosorbent assays. Group and pairwise comparisons of analytes were performed using regression models and area under the receiver operating curves (AUC-ROC). Results: In total, 73 subjects with CP (28 suspected CP and 45 definitive CP) and 40 controls were included. Compared to controls, the median plasma concentrations of sCD163 (P = 0.019) and sCD206 (P = 0.033) were elevated in patients with definitive CP. sCD206 was also elevated in patients with definitive CP (P = 0.042) compared to suspected CP. ROC analysis revealed the optimal sCD163 cutpoint to distinguish definitive CP from controls was 1.84 mg/mL (AUC-ROC 0.65; 95% confidence interval [CI], 0.54-0.77). The optimal sCD206 cutpoint to distinguish definitive CP from controls was 0.24 mg/mL (AUC-ROC 0.66; 95% CI, 0.54-0.78). MCP-1 concentrations showed no differences across subgroups. Conclusion: Our study demonstrates that subjects with definitive CP, sampled during a clinically quiescent phase, exhibited increased levels of sCD163 and sCD206. This indicates the presence of activated M2 macrophages in patients with CP at advanced, but not early, clinical stages.

KW - biomarkers

KW - chronic pancreatitis

KW - immunology

KW - macrophages

UR - http://www.scopus.com/inward/record.url?scp=85211322074&partnerID=8YFLogxK

U2 - 10.1097/MPA.0000000000002443

DO - 10.1097/MPA.0000000000002443

M3 - Journal article

C2 - 39626186

AN - SCOPUS:85211322074

SN - 0885-3177

VL - 54

SP - e331-e339

JO - Pancreas

JF - Pancreas

IS - 4

ER -

Circulating biomarkers of macrophage activation in different stages of chronic pancreatitis: A pilot study

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this